Ivabradine Amarox (Ivabradine Hydrochloride)

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By blocking this current, the drug slows the spontaneous depolarisation of pacemaker cells, reducing heart rate without decreasing the strength of cardiac contraction.

The dose of Ivabradine Amarox is determined by the prescribing clinician based on the patient’s heart rate, clinical condition, and response to therapy. Dosage adjustments are made according to therapeutic goals and tolerability.

Safety of ivabradine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting blood pressure or myocardial contractility. Beta‑blockers act on adrenergic receptors and have broader cardiovascular effects, which may be advantageous or limiting depending on the patient’s overall condition.

Store at ambient temperature: keep the tablets in the original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Ivabradine Amarox is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. It is generally taken with or without food as directed by the prescriber.

The most serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, and rare visual disturbances that may lead to persistent vision loss. Patients should be monitored for these events, especially when initiating therapy or adjusting the dose.

Ivabradine should be avoided in patients with severe hypotension, sick‑sinus syndrome, acute decompensated heart failure, or those taking strong CYP3A4 inhibitors that could raise drug levels. It is also contraindicated in individuals with known hypersensitivity to ivabradine.